{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T08:27:50Z","timestamp":1777710470899,"version":"3.51.4"},"reference-count":32,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T00:00:00Z","timestamp":1590537600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the Practical Research Project for Rare\/Intractable Diseases of the Japan Agency for Medical Research and Development","award":["JP19ek0109356"],"award-info":[{"award-number":["JP19ek0109356"]}]},{"name":"a Health and Labor Sciences Research Grant on Rare and Intractable Diseases from the Ministry of Health, Labor and Welfare of Japan","award":["19FC1007"],"award-info":[{"award-number":["19FC1007"]}]},{"name":"a Grant-in-Aid for Clinical Research from Miyazaki University Hospital"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0233159","type":"journal-article","created":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T17:28:14Z","timestamp":1590600494000},"page":"e0233159","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":8,"title":["Human T-cell leukemia virus type 1 may invalidate T-SPOT.TB assay results in rheumatoid arthritis patients: A retrospective case-control observational study"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1116-5818","authenticated-orcid":true,"given":"Kunihiko","family":"Umekita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yayoi","family":"Hashiba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosho","family":"Iwao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chihiro","family":"Iwao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatoshi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumi","family":"Kariya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyoshi","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunichi","family":"Miyauchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Risa","family":"Kudou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Rikitake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katoko","family":"Takajo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motohiro","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiro","family":"Takajo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eisuke","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiko","family":"Hidaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiko","family":"Okayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2020,5,27]]},"reference":[{"key":"pone.0233159.ref001","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"J Keane","year":"2001","journal-title":"N Engl J Med."},{"key":"pone.0233159.ref002","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1183\/09031936.00028510","article-title":"The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement","volume":"36","author":"I Solovic","year":"2010","journal-title":"Eur Respir J."},{"key":"pone.0233159.ref003","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/art.21043","article-title":"Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists","volume":"52","author":"L Carmona","year":"2005","journal-title":"Arthritis Rheum."},{"key":"pone.0233159.ref004","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1136\/ard.2009.118935","article-title":"Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)","volume":"69","author":"WG Dixon","year":"2010","journal-title":"Ann Rheum Dis."},{"key":"pone.0233159.ref005","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/art.24632","article-title":"Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry","volume":"60","author":"F Tubach","year":"2009","journal-title":"Arthritis Rheum."},{"key":"pone.0233159.ref006","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/clinids\/17.6.968","article-title":"The tuberculin skin test","volume":"17","author":"RE Huebner","year":"1993","journal-title":"Clin Infect Dis."},{"key":"pone.0233159.ref007","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1136\/ard.2004.029041","article-title":"Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis","volume":"64","author":"D Ponce de Le\u00f3n","year":"2005","journal-title":"Ann Rheum Dis."},{"key":"pone.0233159.ref008","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/1471-2334-9-207","article-title":"Performance of the tuberculin skin test and interferon-gamma release assay for detection of tuberculosis infection in immunocompromised patients in a BCG-vaccinated population","volume":"9","author":"EY Kim","year":"2009","journal-title":"BMC Infect Dis"},{"key":"pone.0233159.ref009","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S1473-3099(04)01206-X","article-title":"Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review","volume":"4","author":"M Pai","year":"2004","journal-title":"Lancet Infect Dis"},{"key":"pone.0233159.ref010","first-page":"1","article-title":"Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection\u2014United States, 2010.","volume":"59","author":"GH Mazurek","year":"2010","journal-title":"MMWR Recomm Rep."},{"key":"pone.0233159.ref011","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3899\/jrheum.140101","article-title":"Diagnosis of latent tuberculosis and prevention of reactivation in rheumatic patients receiving biologic therapy: international recommendations","volume":"91","author":"F Iannone","year":"2014","journal-title":"J Rheumatol Suppl."},{"key":"pone.0233159.ref012","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.5588\/ijtld.16.0038","article-title":"Comparative utility of interferon-\u03b3 release assay, QuantiFERON\u00ae TB-GIT and T-SPOT\u00ae.TB in rheumatoid arthritis","volume":"20","author":"R Matsumura","year":"2016","journal-title":"Int J Tuberc Lung Dis"},{"key":"pone.0233159.ref013","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.tube.2017.12.005","article-title":"Utility of the T-SPOT(\u00ae).TB test's borderline category to increase test resolution for results around the cut-off point.","volume":"108","author":"K Rego","year":"2018","journal-title":"Tuberculosis (Edinb.)"},{"key":"pone.0233159.ref014","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/jmv.23181","article-title":"Current prevalence of HTLV-1 in Japan as determined by screening of blood donors","volume":"84","author":"M Satake","year":"2012","journal-title":"J Med Virol"},{"key":"pone.0233159.ref015","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/ijc.2910420605","article-title":"Suppression of tuberculin skin reaction in healthy HTLV-I carriers from Japan","volume":"42","author":"N Tachibana","year":"1988","journal-title":"Int J Cancer."},{"key":"pone.0233159.ref016","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/ijc.2910560307","article-title":"Decreased reactivity to PPD among HTLV-I carriers in relation to virus and hematologic status","volume":"56","author":"SL Welles","year":"1994","journal-title":"Int J Cancer"},{"key":"pone.0233159.ref017","doi-asserted-by":"crossref","first-page":"e6517","DOI":"10.1371\/journal.pone.0006517","article-title":"Abnormally high levels of virus-infected IFN-gamma+ CCR4+ CD4+ CD25+ T cells in a retrovirus-associated neuroinflammatory disorder.","volume":"4","author":"Y Yamano","year":"2009","journal-title":"PLoS One."},{"key":"pone.0233159.ref018","doi-asserted-by":"crossref","first-page":"E691","DOI":"10.3390\/v10120691","article-title":"Cytokine networks dysregulation during HTLV-1 infection and associated diseases.","volume":"10","author":"N Futsch","year":"2018","journal-title":"Viruses"},{"key":"pone.0233159.ref019","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1080\/14397595.2018.1519890","article-title":"The time-sequential changes of risk factors for adult T-cell leukemia development in human T-cell leukemia virus-positive patients with rheumatoid arthritis: a retrospective cohort study","volume":"29","author":"K Umekita","year":"2019","journal-title":"Mod Rheumatol"},{"key":"pone.0233159.ref020","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"FC Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"key":"pone.0233159.ref021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/acr.22783","article-title":"American College of Rheumatology. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis.","volume":"68","author":"JA Singh","year":"2016","journal-title":"Arthr Care Res (Hoboken)."},{"key":"pone.0233159.ref022","unstructured":"Abingdon, UK Oxford Immunotec. T-SPOT.TB package insert PI-TB-US-V5. March 2015. http:\/\/www.oxfordimmunotec.com\/international\/wp-content\/uploads\/sites\/3\/Final-File-PI-TB-US-V6.pdf"},{"key":"pone.0233159.ref023","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"ML Prevoo","year":"1995","journal-title":"Arthritis Rheum"},{"key":"pone.0233159.ref024","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1086\/428625","article-title":"The clonal expansion of human T lymphotropic virus type 1-infected T cells: a comparison between seroconverters and long-term carriers","volume":"191","author":"G Tanaka","year":"2005","journal-title":"J Infect Dis."},{"key":"pone.0233159.ref025","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1002\/jmv.24802","article-title":"Analysis of HTLV-1 proviral load (PVL) and antibody detected with various kinds of tests in Japanese blood donors to understand the relationship between PVL and antibody level and to gain insights toward better antibody testing.","volume":"89","author":"C Matsumoto","year":"2017","journal-title":"J Med Virol"},{"key":"pone.0233159.ref026","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"JS Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"pone.0233159.ref027","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/BOR.0b013e3283025ec2","article-title":"Tuberculosis reactivation during immunosuppressive therapy in rheumatic diseases: diagnostic and therapeutic strategies","volume":"20","author":"J Keane","year":"2008","journal-title":"Curr Opin Rheumatol"},{"key":"pone.0233159.ref028","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/ard.2007.070789","article-title":"Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon gamma assay","volume":"67","author":"G Matulis","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"pone.0233159.ref029","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1182\/blood-2009-12-257410","article-title":"Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan.","volume":"116","author":"M Iwanaga","year":"2010","journal-title":"Blood"},{"key":"pone.0233159.ref030","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1002\/jmv.22087","article-title":"Human T cell lymphotropic virus type 1 (HTLV-1) proviral load of HTLV-associated myelopathy\/tropical spastic paraparesis (HAM\/TSP) patients according to new diagnostic criteria of HAM\/TSP.","volume":"83","author":"MF Grassi","year":"2011","journal-title":"J Med Virol"},{"key":"pone.0233159.ref031","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/acr.22205","article-title":"Treatment with anti\u2013tumor necrosis factor biologic agents in human T lymphotropic virus type I\u2013positive patients with rheumatoid arthritis.","volume":"66","author":"K Umekita","year":"2014","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"pone.0233159.ref032","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/art.40461","article-title":"Brief Report: Attenuated effectiveness of tumor necrosis factor inhibitors for anti-human T lymphotropic virus type I antibody-positive rheumatoid arthritis.","volume":"70","author":"T Suzuki","year":"2018","journal-title":"Arthritis Rheumatol."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0233159","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T17:28:33Z","timestamp":1590600513000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0233159"}},"subtitle":[],"editor":[{"given":"Masataka","family":"Kuwana","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2020,5,27]]},"references-count":32,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,5,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0233159","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,27]]}}}